Synergistic Tumor Treatment with Extended-PK IL-2 & Monoclonal Antibodies
Invention type: Technology
/
Case number: #15627
The present invention relates to methods of treating cancer with a combination of extended-PK IL-2 and one or more therapeutic agents, such as a therapeutic antibody. The methods of the invention are applicable across any type of cancer.
Researchers
Shuning (Annie) Gai
/
Byron Kwan
/
Karl Dane Wittrup
Departments: Department of Chemical Engineering
Technology Areas: Therapeutics: Proteins & Antibodies, Small Molecules
Impact Areas: Healthy Living
-
synergistic tumor treatment with extended-pk il-2 and therapeutic agents
United States of America | Granted | 9,844,582
License this technology
Interested in this technology? Connect with our experienced licensing team to initiate the process.
Sign up for technology updates
Sign up now to receive the latest updates on cutting-edge technologies and innovations.